ArticleScientific reports2025
Chitosan nanoparticles loaded with ribavirin, carboplatin, and thyme oil downregulate SNQ2, ERG11, CDR1, and MDR1 in Candida strains.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bridging the "Valley of Death" in Antifungal Therapy: Next-Generation Biomimetic and Exosome-Inspired Nanocarriers for Invasive Candidiasis.Journal of fungi (Basel, Switzerland) · 2026Review
- Antifungal Activity ofInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined the effects of chitosan nanoparticles (CS-NPs) loaded with ribavirin (CS-R-NPs), carboplatin (CS-C-NPs), and Thymus vulgaris essential oil (CS-TV-NPs) on gene expression in Candida glabrata and Candida tropicalis. C. glabrata and C. tropicalis strains were obtained from Tarbiat Modares University. CS-NPs were synthesized via the ionic gelation method and characterized through dynamic light scattering, electrophoretic light scattering and transmission electron microscopy. Cytotoxicity was assessed via the MTT assay in fibroblasts. The minimum inhibitory concentrations (MICs) of the nanoparticle-encapsulated formulations were determined via the microdilution method per the CLSI-M27-A3/S4 guidelines. The gene expression of SNQ2 and ERG11 in C. glabrata and that of CDR1 and MDR1 in C. tropicalis was quantified via qRT‒PCR. CS-R-NPs, CS-C-NPs and CS-TV-NPs demonstrated high encapsulation efficiencies (81-91%), hydrodynamic diameters of approximately 286-298 nm, and positive zeta potentials (+ 33 to + 34 mV), with a spherical morphology and minimal aggregation. In vitro drug release extended over 64 h, with CS-TV-NPs achieving the highest cumulative release (60%). Cytotoxicity assays indicated that the CS-TV-NPs presented the highest IC50 (20.31 µg/ml). Compared with free drugs, encapsulated formulations significantly lowered the MIC values against C. glabrata and C. tropicalis, enhancing antifungal efficacy. qRT‒PCR confirmed notable downregulation of SNQ2 and ERG11 in C. glabrata and of CDR1 and MDR1 in C. tropicalis, with the most pronounced effects observed in the CS-NP-treated groups. CS-NPs significantly enhanced antifungal efficacy by reducing MIC values and downregulating resistance genes, highlighting their potential as effective drug delivery systems against Candida infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.